|
|
Part 1: Patients (N=19) received 1 st line panitumumab/IFL therapy: Panitumumab 2.5 mg/kg/week administered intravenously over 1 hour in 6-week courses ...
20060314 FOLFIRI + Panitumumab in 1 st-line Treatment of Metastatic CRC . Approx. 56 days after end of treatment . Köhne CH, et al. ASCO-GI 2010, #414, poster ...
Rest of world - often bevacizumab first line, cetuximab 2 nd line, panitumumab 3 rd line. Not VEGF + EGFR together; Survival; 6 -12 -18 -22 …. More if liver ...
panitumumab . Mechanism . bind selectively to. intracellular tyrosine kinase. domain of EGFR . bind specifically to. extracellular ligand-binding
EGFR-H&N-Ca-slides-2011-0331.ppt - Search
slide
WT, wild type; MT, mutant; cmab, cetuximab; CT, chemotherapy; pmab, panitumumab . Objective Response N (%) Reference . Treatment (panitumumab or cetuximab)
Panitumumab vs BSC in Metastatic Colorectal Cancer . Peeters M, et al. AACR 2006. Abstract CP-1. Patients with metastatic colorectal cancer who failed prior ...
3 . In advance of launching our new oncology therapeutic for colorectal cancer (Vectibix ™ (panitumumab)), Amgen performed a coding assessment to determine ...
precon_2c.ppt - Search
appropriate
pmab+bev/Ox-CT bev/Ox-CT 108 (26) 143 (35) Death events (%) NE 19.4 (18.4- 20.8) Median (95%CI), mos HR = 1.43 (95% CI: 1.11–1.83)a Months Panitumumab N Censored N 413 ...
giantonio.ppt - Search
56 . HR: 0.54 (95% CI: 0.44-0.66) P < .0001 . Panitumumab + BSC (n = 231) BSC (n = 232) Panitumumab vs BSC in EGFR-Positive CRC: PFS Results
Single agent panitumumab: N=208 . K-Ras Mutation . Wild-Type K-Ras . Amado RG, et al. J Clin Oncol. 2008;26:1626-1634. Panitumumab registration trial
mcleod.ppt - Search
powerpoint
Randomized, Open-Label, Controlled Phase IIIb Trial of Panitumumab in MCRC–PACCE . Stratification factors: ECOG score, prior adjuvant therapy, disease site ...
1840_Slides.ppt - Search
case
Panitumumab . ABT-751 . Tipifarnib . Matuzumab . AZD6244 . Everolimus . Neratinib . First-line Second/third-line . AS1404 . Bexarotene . Sorafenib . Cetuximab . Bortezomib
The NCCN guidelines note that panitumumab should not be used in combination whereas cetuximab can be used in combination. Recent data also support the use of panitumumab ...
Bardelli A & Siena S. Molecular mechanisms of resistance to Cetuximab and Panitumumab in colorectal cancer, J Clin Oncol. 2010;Jan:e published.
Cetuximab, Panitumumab . EGFR IHC . Imatinib mesylate (Gleevec) c-kit IHC . Trastuzumab (Herceptin) HER-2/neu IHC, FISH & CISH . Drug . Safety Test
2004: Approval of Cetuximab (Erbitux) & Bevacizumab (Avastin) 2006: Approval of Panitumumab (Vectibix) 2008: KRAS mutations predict lack of benefit of ...
Percentage decrease in target lesion greater in patients with wild-type KRAS receiving panitumumab . Patients With Mutant KRAS . Mean in Wks
Blood samples were collected to evaluate the Pks Overall RR:,47% and 32% achieved SD Average progression-free survival was 8.2 months Exposure to panitumumab or CPT-11 ...
saif_umd.ppt - Search
therapies
Anti-EGFR mAbs: cetuximab, panitumumab; Small molecule inhibitors of tyrosine kinase activity (EGFR-TKIs): erlotinib, gefitinib
New targeted therapies include Bevacizumab (blocks blood vessels growth feeding tumor) and Cetuximab and Panitumumab (block hormone pathways promoting cancer ...
|
Hot Documents 童軍las-disciplinas-de-peter-senge an-asian-perspective human-resource-management-an-asian-perspective jose-carlos-marion-contabilidade-basica-fluxo-de-caixa hrm-gary-dessler-chapter 旅行業 gaba-and-benzodiazepine porfirio cultural-influences-employee |